Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
- Previous Close
6.81 - Open
6.82 - Bid 6.80 x --
- Ask 6.81 x --
- Day's Range
6.76 - 6.81 - 52 Week Range
6.42 - 8.68 - Volume
26,347,483 - Avg. Volume
43,470,390 - Market Cap (intraday)
45.138B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
22.67 - EPS (TTM)
0.30 - Earnings Date Apr 28, 2025
- Forward Dividend & Yield 0.07 (0.98%)
- Ex-Dividend Date Sep 30, 2024
- 1y Target Est
6.80
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.
www.raas-corp.comRecent News: 002252.SZ
View MorePerformance Overview: 002252.SZ
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002252.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002252.SZ
View MoreValuation Measures
Market Cap
45.20B
Enterprise Value
41.21B
Trailing P/E
22.62
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.57
Price/Book (mrq)
1.39
Enterprise Value/Revenue
5.07
Enterprise Value/EBITDA
17.26
Financial Highlights
Profitability and Income Statement
Profit Margin
24.64%
Return on Assets (ttm)
3.77%
Return on Equity (ttm)
6.36%
Revenue (ttm)
8.13B
Net Income Avi to Common (ttm)
2B
Diluted EPS (ttm)
0.30
Balance Sheet and Cash Flow
Total Cash (mrq)
4.04B
Total Debt/Equity (mrq)
0.13%
Levered Free Cash Flow (ttm)
-1.32B